WuXi AppTec Co., Ltd. (WUXIF)
Data as of August 11, 2026 · Medical - Diagnostics & Research
Stockbruh grade: Strong 4/5 metrics rated Sunny
What does WuXi AppTec Co., Ltd. do?
WuXi AppTec is a global research and development company that helps discover and manufacture small molecule drugs, cell and gene therapies. Based in Shanghai, they offer a wide range of services including contract research, development, and manufacturing organization services, as well as biology services and seamless drug and medical device testing. They're all about accelerating time to market and revolutionizing the pharmaceutical and biotech industry. 💪🔬🚀.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛈️ Weak | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $20.78 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Returns have been below average recently — worth reviewing valuation carefully before investing. Sign up free to see the full Stockbruh valuation breakdown.
How the business works
WuXi AppTec is a global research and development company that helps discover and manufacture small molecule drugs, cell and gene therapies. Based in Shanghai, they offer a wide range of services including contract research, development, and manufacturing organization services, as well as biology services and seamless drug and medical device testing. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — WuXi AppTec Co., Ltd. appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.